Skip to main content

The clinical course of respiratory tuberculosis in lung cancer patients

Buy Article:

$34.78 + tax (Refund Policy)

OBJECTIVE: To determine the clinical features of lung cancer patients with respiratory tuberculosis (TB), thereby elucidating the clinical course.

SETTING: A tertiary referral hospital in Korea, with intermediate TB prevalence.

DESIGN: A retrospective case-control study involving lung cancer patients in whom respiratory TB was diagnosed concurrently or sequentially.

RESULTS: Of 36 lung cancer patients, 10 (27.8%) were diagnosed with TB concurrently with the diagnosis of lung cancer, while 26 (72.2%) were diagnosed with TB after the diagnosis of lung cancer. The median time from the diagnosis of lung cancer to the diagnosis of TB was 4 months (range −1–47). Five lung cancer patients presented with incidental microbiological or pathological findings. Of the 36 lung cancer patients, eight (22%) had no remarkable changes on chest radiography, while all control group patients had identifiable abnormalities (P < 0.001). In both groups, most patients completed the initially prescribed anti-tuberculosis medications, with some modest modifications. The most common cause of death in the lung cancer group was progression of lung cancer (89.5%).

CONCLUSION: The clinical course of respiratory TB in lung cancer patients does not differ from that in patients without malignancy, suggesting that respiratory TB may not influence the clinical course of lung cancer patients if properly treated.

Keywords: lung cancer; treatment; tuberculosis

Document Type: Regular Paper

Affiliations: 1: Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea 2: Department of Radiology, Kyungpook National University School of Medicine, Daegu, Korea

Publication date: 01 August 2009

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease (IJTLD) is for clinical research and epidemiological studies on lung health, including articles on TB, TB-HIV and respiratory diseases such as COVID-19, asthma, COPD, child lung health and the hazards of tobacco and air pollution. Individuals and institutes can subscribe to the IJTLD online or in print – simply email us at [email protected] for details.

    The IJTLD is dedicated to understanding lung disease and to the dissemination of knowledge leading to better lung health. To allow us to share scientific research as rapidly as possible, the IJTLD is fast-tracking the publication of certain articles as preprints prior to their publication. Read fast-track articles.

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content